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Aim: The purpose of the present study is to evaluate the potent growth inhibitory effects of aqueous wheatgrass extract (AWE) alone 
and in combination with cisplatin on human breast and cervical cancer cells. Materials and Methods: The cytotoxic potential of AWE 
alone and in combination with cisplatin was evaluated on human breast and cervical cancer cells (MCF-7 and HeLa) by cell viabil-
ity assay. Further, the mode of cell death induced by AWE was determined by nuclear morphological examination and cell cycle 
analysis. These effects were then correlated with the expression of genes involved in apoptosis and proliferation (cyclin D1 and Bax) 
by RT-PCR. Results: AWE showed dose- and time dependent selective cytotoxicity towards the cancerhighlighting its safe profile. 
Lower dose combinations of AWE and cisplatin induced increased growth inhibition compared with the individual drugs on both cell 
lines (combination index < 1) indicating strong synergistic interactions. AWE was found to induce apoptosis and arrested the cells 
at G0–G1 phase of the cell cycle which correlated with the modulation of expression of bax and cyclin D1 in a time-dependent man-
ner in MCF-7 and HeLa cells. Conclusion: These results suggest that the anti-cancer potential of AWE may be due to apoptosis 
induction and its anti-proliferative properties. This study also provides the first evidence demonstrating synergism between AWE 
and cisplatin, which may enhance the therapeutic index of prevention and/or treatment of human breast and cervical cancer.
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Cancer is a multistep and multifactorial disorder, 
involving aberrations in the genetic and epigenetic 
makeup of the cells, influenced directly and indirectly 
from the environmental factors which account for 
almost 90–95% of all cancer cases [1, 2]. Numerous 
phytonutrients, such as sulforaphane, genistein, res-
veratrol, curcumin, β-elemene etc. derived from edible 
plants are the foremost prospective agents reported 
to interfere with different stages of carcinogenesis and 
many other health conditions, including cardiovascular 
diseases, diabetes etc. Mounting scientific reports 
on these dietary agents corroborate that a diet rich 
in fruits and vegetables could reduce 7–31% of all 
cancers worldwide [3–5]. These phytonutrients act 
through multiple signalling pathways which make these 
agents important for cancer prevention and therapy. 
Concurrent therapies, utilizing these nutrients along 
with other standard cancer treatment modalities like 
chemotherapy, are one of the current thrusted areas 
to enhance the therapeutic index by synergistic or ad-
ditive interactions between these drugs [6, 7].
Wheat (Triticum aestivum), one such phytonutri-
ent, is an important part of human diet, and epide-
miological studies have suggested its protective role 
against many chronic diseases including thalassemia, 
cancer etc [8–10]. A number of studies have used 
wheat in various forms such as whole grain, wheat-
grass etc. (5–10 day old grass of the common wheat 
plant) [10–12]. Wheatgrass contains selenium, laetrile, 
vitamins C and E, beta carotene, ferulic acid and va-
nilic acid, phenolic compounds including flavonoids, 
the concentrations of which increase with the ger-
mination  period [11, 12]. It has been shown to inhibit 
the metabolic activity of carcinogens and has anti-
mutagenic and antioxidant activities and can reduce 
chemotherapy associated side-effects [13–18].
The present study was designed to evaluate the po-
tent growth inhibitory effects of aqueous wheatgrass 
extract (AWE) alone and in combination with cisplatin 
on human breast cancer, MCF-7 and human cervical 
cancer, HeLa cell lines. Further, its effect on the modu-
lation of genes involved in proliferation and apoptosis 
were analyzed to understand the chemopreventive 
mechanism of wheatgrass.
MATERIALS AND METHODS
Cancer cell lines.The effect of AWE alone and 
in combination with cisplatin was studied on human 
breast carcinoma cell line (MCF-7) and human cer-
vical carcinoma cell line (HeLa) obtained courtesy 
of Dr. Tahir Rizvi, UAE University, Al Ain, UAE. The cells 
were maintained in DMEM supplemented with 
10% FBS, penicillin (100 units/mL), and incubated 
at 37 °C in a humidified atmosphere with 5% CO2. 
Lymphocytes were isolated from healthy non-smoking 
donors using HiSep Media (HiMedia, India) as per 
the manufacturer’s instructions and were maintained 
in RPMI media (Sigma, USA) [6].
Preparation of drug solutions. AWE was pre-
pared as previously described [19]. Briefly, wheat 
seeds were purchased from the local market, washed 
with tap water, followed by distilled water. The seeds 
were soaked in distilled water for 9 h and transferred 
to containers with soil. The wheatgrass was collected 
on day 11. Only wheatgrass of uniform size, shape and 
without injuries were selected. The wheatgrass was 
washed, wiped and cut into small pieces. A 30% (w/v) 
aqueous extract was prepared (stock) using a clean 
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mortar and pestle to make a homogenized paste. 
The extract was centrifuged at 15,000 rpm for 20 min 
at 4 oC and filtered using 0.2 μm filter. The purified 
extract was stored at -20 oC in aliquots until further 
use. Further dilutions were made from the 30% stock 
in complete medium to required concentrations be-
tween 1–25% for the treatment of MCF-7 cells, HeLa 
cells and lymphocytes.
A stock solution of 3.3 mM of cisplatin (Cadila 
Pharmaceuticals Ltd, India) was used to make drug 
dilutions of varying concentrations(1–200 μM) in com-
plete medium.
Cell viability assay. The anti-proliferative acti-
vity of AWE (1–25%) and cisplatin (1–200 μM) alone 
or in combination (1 and 5% AWE; 1 and 5 μM cis-
platin) on MCF-7 cells, HeLa cells and lymphocytes 
was evaluated using the MTT (3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide) assay, 
as previously described  [20]. In short, the cells were 
plated at a density of ~1 • 104 cells/well in 96-well 
plates in triplicates. Next day the culture medium was 
removed and replaced by varying concentrations 
of AWE (1–25%) or cisplatin (1–200 μM) in complete 
medium or by the combination doses and incubated 
for 24 and 48 h. The MTT assay was performed and 
the optical density (OD) was measured at 570 nm. 
The percent viability was calculated as (OD of the drug-
treated sample/OD of the non-treated sample) x 100, 
considering that the colorimetric signal is directly 
proportional to the number of viable cells. This assay 
allows measurement of growth rate and conversely, 
when metabolic events lead to apoptosis or necrosis, 
the reduction in cell viability. The EC50 (50% effective 
concentration) values were calculated from the dose–
response curves.
Calculation of combination effects of cisplatin 
and AWE. Calculations of combination effects were 
based on the method of Chouand Talalay (1984) and 
were expressed as a combination index (CI) [21]. 
CI analysis provides qualitative information on the na-
ture of drug interaction, and CI, a numerical value, was 
calculated according to the following equation:
CI = CA,x/ICx,A + CB,x/ICx,B,
where, CA,x and CB,x are, respectively, the concentra-
tions of drugs A and B used in combination to achieve 
x% drug effect. ICx,A and ICx,B are the concentrations 
for single agents to achieve the same effect. A CI value 
< 1, =1, or > 1 represents, respectively, synergy, ad-
ditivity, and antagonism of cisplatin and wheatgrass, 
respectively.
Detection of apoptosis in MCF-7 and HeLa 
cells after treatment with AWE
Microscopic examination. Morphological 
 changes in MCF-7 and HeLa cells were observed 
on treatment with AWE and cisplatin at different con-
centrations (5, 15 and 25%) for 24 and 48 h  using 
a normal inverted microscope (Labomed, USA). 
The untreated cells were used as negative control.
Nuclear morphological studies. Apoptosis 
induction after treatment with AWE at the EC50 con-
centration (15 and 25% for MCF-7 and HeLa cells, 
respectively) for different time intervals (0, 6 and 
24 h) was evaluated by the nuclear morphological 
changes associated with it using propidium iodide 
staining [20]. Briefly, ~106 cells/ml cells were seeded 
on glass coverslips and incubated overnight in com-
plete medium at 37 °C. Further, cells were treated with 
AWE at its EC50 for a series of time periods (0, 6 and 
24 h). At the end of the desired time interval, cells 
were fixed in a mixture of acetone: methanol (1:1) at 
-20 oC for 10 min, washed with 1X PBS (pH 7.4) twice 
and stained with propidium Iodide (10 mg/ml in PBS) 
for 30 s in dark at RT. The coverslips were thoroughly 
washed with PBS and placed upturned onto a glass 
slide with mounting media (DPX). Slides were viewed 
at 515 nm under the Progress Fluorescent Micro-
scope (Olympus, USA). The images were captured at 
×40 magnification.
Quantification of apoptotic cells by flow cyto-
metry. AWE-induced apoptosis in MCF-7 and HeLa 
cells was determined by flow cytometric analysis 
as described earlier [20]. After treatment of syn-
chronous cultures of MCF-7 and HeLa cells with AWE 
at their respective EC50 for 0 and 24 h, both adherent 
and floating cells were harvested, washed with phos-
phate buffered saline (PBS, pH 7.2) and fixed with 
ice-cold absolute ethanol at -20 oC overnight. Cells 
were then washed with PBS prior to resuspending 
in a buffer containing PI (50 mg/ml), 0.1% sodium 
citrate, 0.1% Triton X-100 and 100 mg/ml of RNase A. 
The cells were analyzed using flow cytometry (Beck-
man Coulter Flow Cytometer FC500, CXP Version 2.2). 
The data was analyzed using the Beckman Coulter 
KALUZA 1.1 analysis software.
Expression analysis of various genes targeted 
by AWE. Reverse transcription-PCR was used to de-
tect the expression of Bax and cyclin D1 in response 
to treatment with AWE at EC50 for varying time points 
(0, 6 and 24 h). Total RNA extraction from untreated 
and AWE-treated MCF-7 and HeLa cells was carried 
out as per the manufacturer’s instructions (GenElute 
Mammalian Genomic Total RNA Kit, Sigma, USA) 
at various time intervals. Further, total RNA was 
subjected to first strand synthesis as per manufac-
turer’s protocol (ProtoScript M-MuLVTaq RT-PCR Kit, 
New England Biolabs, USA) followed by PCR using 
gene-specific primers [20, 22, 23]. в-Actin was taken 
as an internal control. The PCR cycle was as fol-
lows: initial denaturation at 95 oC for 5 min, followed 
by 35 amplification cycles (denaturation at 94 oC for 
30 s, annealing at 55 oC for в-actin, 56 oC for Bax and 
54 oC for cyclin D1 for 30 s, and extension at 72 oC for 
45 s), with final extension at 72 oC for 7 min. Amplified 
products were visualized on a 2% agarose gel conta-
ining ethidium bromide.
Statistical analysis. All data are expressed 
as means ± SD of at least 3 experiments. Fisher’s exact 
test was adopted for statistical evaluation of the results. 
Significant differences were established at p < 0.05.
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RESULTS
AWE selectively suppresses the viability 
of MCF-7 and HeLa cells. The growth suppres-
sive effects of different concentrations of AWE 
on MCF-7 cells, HeLa cells and lymphocytes were 
evaluated by the MTT assay. AWE treatment at vari-
ous concentrations ranging from 1–25% for 24 and 
48 h induced cell death in MCF-7 and HeLa cells 
in a dose and time-dependent manner (Fig. 1 a, b). 
The EC50 for MCF-7 cells was found to be 15% and 
10% whereas for HeLa cells, it was found to be 25 and 
15%, respectively, for 24 and 48 h. The experiment was 
reproduced at least three times.
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Fig. 1. Selective cytotoxicity of AWE on MCF-7 and HeLa cells 
(a, b). MCF-7 and HeLa cells treated with AWE at varying con-
centrations (1–25%) results in dose and time dependent growth 
suppression at 24 h (EC50 = 15%, 25%, respectively) and 48 h 
(EC50 = 10%, 15%, respectively) whereas treatment of lympho-
cytes with AWE at similar concentrations for 24 h was found 
to be minimally cytotoxic (c). Values are means ± SD of three 
independent experiments. Each value with AWE treatment differs 
from the control value (p < 0.05)
In order to confirm the safety profile of AWE, its ef-
fect was determined on lymphocytes as normal cells. 
Isolated lymphocytes from a healthy non-smoker adult 
were plated in triplicates followed by treatment with 
AWE at varying doses (1–25%) for 24 h (see Fig. 1 c). 
AWE treatment did not result in a significant decrease 
in cell viability of lymphocytes thus indicating that 
AWE is differentially cytotoxic to cancer cells but not 
to the normal cells. This feature of AWE may provide 
a platform for its development as a safe drug for treat-
ment for breast and cervical cancer.
Cisplatin induces cell death in both cancer and 
normal cells. The effect of increasing concentrations 
(1–200 μM) of cisplatin on the viability of MCF-7, HeLa 
cells and lymphocytes was determined by MTT assay. 
Cisplatin was found to induce dose dependent cyto-
toxicity in these cells as compared to the untreated 
controls. The EC50 of cisplatin on MCF-7 and HeLa cells 
was found to be 200 μM and 75 μM, respectively, after 
24 h treatment (Fig. 2). Importantly, it was found that 
cisplatin reduced the viability of lymphocytes (normal 
cells) (see Fig. 2). Thus this study provides an insight 
into the observed side-effects of chemotherapy seen 
in patients which can be extrapolated in vitro.
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Fig. 2. Cisplatin is cytotoxic to both cancer and normal 
cells. Cisplatin treatment at varying doses (1–200 μM) for 
24 h induced dose-dependent cytotoxicity in MCF-7, HeLa and 
lymphocytes. The EC50 of cisplatin was found to be 200 and 
75 μM at 24 h in MCF-7 and HeLa cells. Values are means ± 
SD of three independent experiments. Each value with cisplatin 
treatment differs from the control value (p < 0.05)
Combination treatment of wheatgrass and 
cisplatin on HeLaand MCF-7 cells. Combinational 
therapy utilizing the currently available chemothera-
peutic drugs with the natural dietary agents is a promi-
sing treatment strategy to reduce the non-specific 
cytotoxicity caused by chemotherapeutic agents such 
as cisplatin. In this study, a combination of wheatgrass 
and cisplatin was evaluated by cell viability assay 
to minimize the side effects and potentiate the che-
motherapeutic activity of cisplatin.
Cells (MCF-7/ HeLa) were treated with different 
concentrations of cisplatin and wheatgrass alone, and 
in combination for 24 h and their viability was evalu-
ated. It was observed that 1 μM of cisplatin (C1) used 
in combination with 1% (W1) and 5% (W2) wheatgrass 
resulted in a significant decrease in cell viability (85 and 
80%, respectively) of MCF-7 cells as compared 
to either of the compounds alone (98% for C1, 97% 
and 90% for W1 and W2). When these combinations 
were used on HeLa cells, the combinations resulted 
in 60 and 53% (for C1W1 and C1W2) decrease in cell 
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viability while individual drugs decreased the cell vi-
ability by 84% for C1 and 81 and 75% with W1 and W2, 
respectively (Fig. 3). Also, treatment of MCF-7 and 
HeLa cells with 5 μM of cisplatin (C2) combined with 
W1 and W2 resulted in synergistic decrease in cell vi-
ability (81 and 70% for MCF-7; 50 and 45% for HeLa) 
as compared to individual doses (C2 = 93% and 77% 
for MCF-7 and HeLa; W1 and W2) (see Fig. 3). Further 
combinational index was calculated and it was found 
to be less than 1 for all the combinations indicative 
of synergistic action of these combinations on both 
MCF-7 and HeLa cells.
0
10
20
30
40
50
60
70
80
90
100
110
C1 C2 W1 W2 C1W1 C1W2 C2W1 C2W2
Combinations of cisplatin and wheatgrass
Ce
ll 
via
bi
lit
y,
 %
MCF-7
HeLa
Fig. 3. Concurrent treatment of MCF-7 and HeLa cells with 
sub-lethal doses of cisplatin (C1 and C2) and AWE (W1 and W2) 
was found to induce synergistic decrease in cell viability in these 
cells (combination index (CI < 1). Each value is a ratio of the level 
in the treated cells to that in the untreated control cells. Values are 
means ± SD of 3 independent experiments. Each value with cis-
platin and AWE treatment differs from the control value (p < 0.05).
AWE induces cell  death via apoptosis 
in MCF-7 & HeLa cells
Morphological changes induced by wheat-
grass on MCF-7 & HeLa cells. MCF-7 and HeLa cells 
treated with increasing concentrations of wheatgrass 
(5, 15 and 25%) for 24 and 48 h were observed under 
an inverted microscope and their morphological cha-
racteristics were noted. Treated cells, as compared 
to untreated cells, showed typical rounding off of cells, 
along with cell shrinkage indicating that wheatgrass 
induces cell death by apoptosis in these cells. The in-
crease in these characteristics was in a dose and 
time-dependent manner (Fig. 4 a, b).
Nuclear morphological changes induced 
by AWE on MCF-7 & HeLa cells. The apoptotic 
changes induced by AWE were verified by analyzing 
various nuclear morphological characteristics with 
or without treatment. Untreated MCF-7 and HeLa 
cells appeared uniform in chromatin density with 
an intact nucleus. On the other hand, AWE treatment 
of MCF-7 (15% AWE) and HeLa (25% AWE) cells for 
6 and 24 h resulted in evidences of apoptosis like 
chromatin fragmentation, accumulation of nuclear de-
bris, apoptotic bodies and nuclear blebbing (Fig. 5 a, 
b).With an increase in duration of AWE exposure, there 
was a cumulative accrual of the said features consis-
tent with apoptosis (see Fig. 5 a, b).
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Fig. 4. Morphological changes induced by AWE treatment 
in MCF-7 (a) and HeLa cells (b) at varying concentrations. AWE 
treatment (at 5, 15 and 25% for 24 and 48 h) of MCF-7 (a) and 
HeLa (b) cells results in characteristic rounding off (arrows) 
of these cells compared to untreated cells. These changes accu-
mulated with an increase in the dose and time of AWE treatment 
(magnification ×100)
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Fig. 5. The nuclear morphological changes induced by AWE 
treatment at various time intervals (0, 6 and 24 h) on MCF-7 (a) 
and HeLa (b) cells. Untreated MCF-7 and HeLa cells (0 h) show 
large and prominent nuclei indicating no significant characte-
ristics of apoptosis (white arrows). MCF-7 (a) and HeLa (b) cells 
treated with AWE at their respective EC50 for 6 and 24 h showed 
time-dependent increase in nuclear morphological changes 
associated with apoptosis such as nuclear condensation and 
fragmentation (green arrows) and apoptotic bodies (yellow ar-
rows) (magnification ×400)
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Effect of AWE on the cell cycle distribution. 
MCF-7 and HeLa cells were exposed to AWE at their 
respective IC50 concentrations (15 and 25%, respec-
tively) for 0 and 24 h and their cell cycle distribution was 
examined by flow cytometry. Flow cytometric analysis 
of control and AWE-treated cells showed proper dis-
tribution of cells in the different phases of cell cycle 
in untreated cells (0 h), while on treatment with AWE 
for 24 h resulted in a significant increase in the number 
of cells in the G0–G1 phase of the cell cycle (80% for 
MCF-7 and 76% for HeLa). Furthermore, AWE treat-
ment caused a significant inhibition in the movement 
of cells into the S-phase (9% for MCF-7 and 11.5% for 
HeLa) in comparison to the untreated cells, respec-
tively (Fig. 6).
0
10
20
30
40
50
60
70
80
90
0 h 24 h 0 h 24 h
G0-G1 phase
S phase
G2-M phase
Ce
ll 
cy
cl
e 
di
st
rib
ut
io
n,
 %
MCF-7 HeLa
Fig. 6. Cell cycle arrest by AWE in MCF-7 and HeLa cells. DNA 
content in different phases of the cell cycle was measured 
using propidium iodide by flow cytometry. MCF-7 and HeLa 
cells(~1•106) treated at their respective EC50 doses of AWE for 
24 h showed a significant decrease in the proportion of cells 
in the G2/M and S phases of the cell cycle while an increase 
in the number of cells in the G0–G1 phase indicating that AWE 
treatment results in cell cycle arrest in this phase in MCF-7 and 
HeLa cells. The histogram shows % analysis of cells in the dif-
ferent phases of the cell cycle from a representative experiment 
(out of three individual experiments)
AWE treatment significantly modulates the ex-
pression of Bax and cyclin D1. In order to determine 
the molecular targets of AWE on MCF-7 and HeLa 
cells, we analyzed the expression of Bax and cyclin 
D1 before and after treatment with AWE. β-Actin was 
used as an internal control for comparison of samples.
Bax, a pro-apoptotic Bcl-2-family protein, resides 
in the cytosol and translocates to mitochondria upon 
induction of apoptosis. The expression of Bax was 
found to be low in both untreated MCF-7 and HeLa 
cells. Upon treatment with AWE, we observed that 
there was a significant rise in the expression of Bax 
in a time dependant manner in MCF-7 and HeLa cells 
(Fig. 7 a, b). Another important gene involved in cell cy-
cle regulation, cyclin D1, functions in the progression 
of the cell from G1 to S phase, and is over-expressed 
in  cancerous cells. In this study, it was also found 
to be expressed in high levels in both the untreated 
cell lines (see Fig. 7 a, b). Interestingly, the expression 
of cyclin D1 significantly decreased in these cells after 
treatment with AWE for 6 and 24 h compared to un-
treated cells (see Fig. 7 a, b).
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Fig. 7. MCF-7 (a) and HeLa (b) cells treated with AWE at their 
respective EC50 doses for 6 and 24 h show a significant decrease 
in the expression of cyclin D1 while a significant upregulation 
in the expression of Bax in a time-dependent manner compared 
to untreated cells. Lanes 1–4 represent untreated cells, cells 
treated with AWE for 6 and 24 h, and negative control for RT-PCR 
respectively. β-Actin was used as an internal control
DISCUSSION
Chemoprevention is a promising interventional ap-
proach utilizing mainly phytochemicals that possess 
many health benefits mediated directly or indirectly 
by modulating signal transduction pathways [7, 24]. 
Ambit reports indicate their important role in cancer 
prevention and treatment owing to their relatively 
safe cytotoxicity profile. Standard cancer therapies 
include surgery, radiotherapy, chemotherapy etc., 
but their successful therapeutic outcome is limited 
due to various side effects and development of multi-
drug resistance thus necessitating a need for alternate 
or adjuvant therapies. Hence, phytochemical based 
therapeutic strategies may help in minimizing these 
side effects as well as prevent the transformation 
of precancerous lesions or development of secon-
dary or second primary tumors. Studies are underway 
to harness the potential of combinational approaches 
utilizing one or more synthetic or natural phytochemi-
cals along with an effective drug such as chemothera-
py to enhance the therapeutic effects of conventional 
cancer therapy [7, 24, 25].
The present focused on unraveling the chemopre-
ventive and therapeutic action of wheatgrass (AWE) 
and decipher its molecular targets on human cancer 
cells. In order to determine the differential cytotoxicity 
towards cancer cells, the effect of varying concentra-
tions of AWE was evaluated on MCF-7, HeLa cells and 
lymphocytes. It was found that AWE inhibited the cell 
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viability of the cancer cells in a dose and time dependant 
manner and its EC50 (effective concentration, the dose 
which reduces the viability of cells by 50%) was deter-
mined to be 15 and 10% on MCF-7 cells, and 25 and 
15% on HeLa cells after 24 and 48 h treatment, respec-
tively (see Fig. 1 a, b). These results are in line with other 
in vitro studies that have shown the growth inhibitory 
effects of wheatgrass on several cancer cells including 
leukemia, skin, prostate cancer cells [17, 19, 26, 27]. 
To qualify that AWE can be used as a safe chemopre-
ventive agent, its effect on normal cells (lymphocytes) 
at various concentrations was determined for the first 
time. It was found that AWE treatment of lymphocytes 
for 24 h did not result in a significant toxicity towards 
these cells (see Fig. 1 c). This property of selectively 
cytotoxicity ofAWE provides evidence that it can be used 
as a safe modality for cancer treatment. This is consis-
tent with the previous studies which found that many 
phytochemicals such as curcumin, sulforaphane etc. 
are minimally toxic to the normal cells [28, 29].
As mentioned before, the combinational strategies 
for cancer treatment are considered more favourable 
due to their higher efficacy, resulting in better sur-
vival rates. Cisplatin is widely used chemotherapeutic 
drug but its efficacy is limited by the associated many 
side-effects like nausea and vomiting, nephrotoxicity, 
alopecia, etc. because of its high toxicity to normal 
cells [30]. In this study, first we analyzed the effect 
of cisplatin on MCF-7, HeLa cells and lymphocytes for 
24 h. It was found that cisplatin inhibited the growth 
of cancer cells in a dose dependant manner with 
the EC50 at 200 μM and 75 μM for MCF-7 and HeLa, 
respectively (see Fig. 2). Moreover, cisplatin also 
induced significant decrease in cell viability of nor-
mal lymphocytes though at higher doses compared 
to the cancer cells, thus confirming that its non- 
specific cytotoxicity towards cancer and normal cells 
which may account for its observed side-effects 
in clinical settings (see Fig. 2). Previous studies have 
shown that cisplatin is aneffective cytotoxic drug used 
in the treatment of several tumour types including lung, 
bladder, testicular, and ovarian cancer with associ-
ated side-effects. In addition some patients develop 
resistance on prolonged exposure to cisplatin [30–32].
Taking into account the observed non-specific cy-
totoxicity of cisplatin, low-dose combination treatment 
using cisplatin and AWE was analyzed on MCF-7 and 
HeLa cells. Our results showed that AWE potentiated 
the growth inhibitory effects of cisplatin at sub-lethal 
doses. Fig. 3 shows that after treatment of MCF-7 cells 
with 1 μM of cisplatin (C1) in conjunction with 1% 
AWE (W1), there was a synergistic (CI < 1) decrease 
in the cell viability (85%) in combination treatment 
(C1W1) than achieved with individual doses (98 and 
97% for cisplatin and AWE alone respectively). Also, 
the other lower dose combinations of cisplatin and 
AWE i.e., C1W2, C2W1 and C2W2 (where C2 = 5 μM, 
W2 = 5%) showed combination index less than 1 indi-
cating a sy nergistic action of these drugs in combina-
tion at the doses used (see Fig. 3). Similar results were 
obtained on treatment of HeLa cells with the same 
combinations (C1W1, C1W2, C2W1 and C2W2) (see 
Fig. 3). This implies that AWE enhances the efficacy 
of cisplatin in killing cancer cells, especially at lower 
doses, thereby minimizing the cytotoxicity to normal 
cells. Similar studies on various cancer cells using cis-
platin in combination with other agents such as EGCG, 
β-elemene, AT-101, honey bee venom, etc. have 
shown cisplatin to act in a synergistic manner [33–37]. 
Thus, combination treatment approaches of cisplatin 
with phytochemicals such as wheatgrass may have 
immense prospects for development of therapeutic 
strategies to overcome cisplatin associated resistance 
and side-effects in human cancers.
Importantly, preventive and therapeutic inter-
ventions ought to induce cell death via induction 
of apoptosis and not necrosis which is associated with 
extensive tissue damage resulting in an inflammatory 
response. The mode of cell death induced by AWE was 
firstly observed by microscopic examination of AWE 
treated MCF-7 and HeLa cells at various concentra-
tions (5, 15 and 25%) for 24 and 48 h. AWE treated 
cancer cells showed characteristic rounding off, cell 
shrinkage and detachment from the matrix, indicating 
that cell death induced by AWE is through apoptotic 
pathway as compared to untreated cells in which these 
morphological changes were absent (see Fig. 4 a, b).
Further, to verify the apoptosis induced by AWE 
in MCF-7 and HeLa cells, changes in the nuclear mor-
phology were examined. Treatment of these cells with 
AWE (15 and 25% for MCF-7 and HeLa respectively) for 
varying time points (6 and 24 h) showed accumulation 
of characteristics changes in the nuclear morpho-
logy viz., nuclear condensation and fragmentation, 
extensive blebbing and presence of apoptotic bodies 
in these cells which increased in a time-dependent 
manner in comparison to untreated cells marked 
by uniform and intact nucleus (see Fig. 5 a, b).
Cell cycle analysis by flow cytometry was per-
formed to confirm the mode of cell death. It was ob-
served that AWE treatment of MCF-7 and HeLa cells 
at their respective EC50 concentrations for 24 h resulted 
in increased proportion of cells in the G0/G1 phase 
of the cell cycle indicating that AWE causes growth 
arrest of these cells at G0/G1 phase of the cell cycle 
in comparison to the untreated controls (see Fig. 6). 
Our studies confirm that AWE induces cell death 
in these cells mediated by the apoptotic pathway. 
Another study also indicated that wheatgrass induces 
apoptosis in human acute promyelocytic leukemia 
cells [26]. Other chemopreventive agents have also 
been found to induce apoptosis in various cancer 
cells [20, 38–42].
The mechanism of apoptosis involves expres-
sion of several genes and pathways. To authenticate 
the cell cycle inhibitory and apoptosis-inducing 
activity of AWE, the expression of cyclin D1, an onco-
genic G1 cyclin and Bax, a pro-apoptotic gene were 
analyzed. Cyclin D1, a key regulator of cell cycle 
 progression, forms a complex with CDK 4 and 6 (cy-
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clin dependant kinases) which phosphorylates the 
retinoblastoma (Rb) protein, thus allowing the pro-
gression of cells from G1 to S phase in the cell cycle 
[43]. The overexpression of cyclin D1 has been linked 
to the development and progression of cancer [44, 
45]. Treatment of MCF-7 and HeLa cells with 15 and 
25% AWE for 6 and 24 h resulted in significant down-
regulation in the expression of cyclin D1 in a time 
dependant manner in comparison to untreated cells 
which showed a high level of expression of cyclin 
D1 (Fig. 7 a, b). Consequently the cell cycle arrest 
mediated by AWE in MCF-7 and HeLa cells might 
be through the modulation of cyclin D1 expression. 
These results are consistent with other studies which 
showed that many chemopreventive agents act 
by downregulating the expression of cyclin D1 [46–48]. 
Thus, cyclin D1 may be an important target for cancer 
chemoprevention and therapy.
Bax, a member of the bcl-2 family, plays a major 
role in apoptosis. Gamut reports suggest that evasion 
of apoptosis in cancer cells may be correlated with 
the low expression of Bax [49–51]. Untreated MCF-7 and 
HeLa cells showed no or feeble expression of Bax while 
on treatment of these cells with AWE for 6 and 24 h, the 
expression of Bax was significantly upregulated in a time-
dependent manner (see Fig. 7 a, b). Studies have impli-
cated the role of Bax in induction of sensitization towards 
therapy as well as in cell cycle arrest and programmed 
cell death [52, 53]. Various chemopreventive agents 
have been shown to induce aforementioned activities 
which have been correlated with increased expression 
of Bax [53–57]. Taken together, the pro-apoptotic and 
anti-proliferative activity of AWE may be related to its ef-
fect of the expression of Bax.
Conclusively, wheatgrass exhibits tumoricidal 
effects and acts as a biological response modifier 
in cancer treatment by inducing apoptosis and cell 
cycle arrest. These results provide new insights that 
wheatgrass may serve as an alternative approach for 
cancer prevention and therapy by potentiating avai-
lable treatments. Additional in vitro and in vivo studies 
are needed to assess the application of wheatgrass for 
therapeutic purposes.
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